Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Birch triterpenes by Chiesi Farmaceutici for Radiodermatitis: Likelihood of Approval
Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis. According to GlobalData, Phase...
Data Insights
Birch triterpenes by Chiesi Farmaceutici for Radiodermatitis: Likelihood of Approval
Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis. According to GlobalData, Phase...